
WolverHeme Happy Hour
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks!
Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Latest episodes

Jul 11, 2025 • 59min
Episode 37: Spilling Drinks over Cytarabine Dosing
In this episode, Bernie and Anthony talk about some BIG changes in cytarabine dosing in AML consolidation after a recent practice changing article. Will this change your practice? Hunault, et al. NEJM. 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400326

May 28, 2025 • 43min
Episode 36: ODAC - Our Decisions Are Confusing
In this episode, Bernie and Anthony are joined by the Myeloma Man Dr. Manni Mohyuddin and lymphoma expert Dr. David Russler-Germain to discuss the very recent ODAC decisions on the STARGLO (glofitamab + GemOx) and AQUILA (daratumumab for smoldering multiple myeloma) trials. Did ODAC do their due diligence, or are there double standards? There is a lot to unpack in this episode!

May 5, 2025 • 1h 11min
CSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically Examined
This is a special encore video presentation of Anthony and Bernie teaming up with the Common Sense Oncology Journal Club series to discuss the SWOG1826 and STARGLO clinical trials. Tycel Phillips, MD, and Manju Sengar, MD join Anthony and Bernie for a great discussion of the trials and how they should impact practice! Join the Common Sense Oncology movement here! https://commonsenseoncology.org/

Apr 7, 2025 • 60min
Dex and the Cytokine City: Managing CRS with Bispecifics
Joining the discussion are Victoria Nachar, an outpatient hematology pharmacist from the University of Michigan with expertise in lymphoma and myeloma, and James Davis, a malignant hematology pharmacist and assistant professor at MUSC, known for his deep knowledge in multiple myeloma. They explore the management of cytokine release syndrome (CRS) in patients receiving bispecific antibodies, comparing it to CAR-T therapies. They discuss current treatment strategies, the role of prophylactic tocilizumab, and the importance of tailored approaches in patient care.

Mar 11, 2025 • 1h 5min
LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML
Join Dr. Anand Patel, a hematology MD and leading educator, alongside Dr. Charlie Foucar, a brilliant hematologist, as they delve into the controversial journey of gemtuzumab in treating acute myeloid leukemia (AML). They discuss its dramatic rise and fall, backed by intriguing studies and data interpretations. Hear them analyze treatment outcomes and dosing strategies while unpacking biases in clinical research. Their engaging banter, peppered with humor and personal anecdotes, makes complex medical discussions entertaining and enlightening!

Jan 21, 2025 • 1h 6min
Episode 32: Navigating a BlinatumoMAD World
In this episode, Anthony and Bernie are joined by two special guests to discuss recent updates to the use of blinatumomab in both adult and pediatric acute lymphoblastic leukemia (ALL), including the results of the AALL1731 trial and the full publication of ECOG1910.
Julia Brown, PharmD, a Pediatric Hematology/Oncology Clinical Pharmacist and Lydia Benitez, an Adult Outpatient Leukemia Clinical Pharmacist bring their unique perspectives and expertise on the proper incorporation of blinatumomab into ALL care, as well as some of the major practical nuances that will be helpful to providers across the globe!
Finally, for all of the Oncology Pharmacists in the audience, don't forget to fill out the HOPA Practice Outcomes and Professional Benchmarking Committee Survey!

Jan 15, 2025 • 49min
The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma
AQUILA is a constellation shaped like an eagle, and also a hotly debated myeloma trial of daratumumab in smoldering multiple myeloma. In this episode, Bernie and Anthony are joined by myeloma expert Manni Mohyuddin to discuss the study's findings and whether or not they should change practice! Grab a drink and listen in for an exciting discussion.
Note: L'aquila is Italian for eagle!
AQUILA: Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Epub ahead of print. PMID: 39652675.

Dec 24, 2024 • 1h 4min
Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates
In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!
Some selected abstracts:
EA4151:
https://ash.confex.com/ash/2024/webprogram/Paper212973.html
Triangle Updates:
https://ash.confex.com/ash/2024/webprogram/Paper200735.html ,
https://ash.confex.com/ash/2024/webprogram/Paper201441.html
EA4181:
https://ash.confex.com/ash/2024/webprogram/Paper194641.html
ENRICH:
https://ash.confex.com/ash/2024/webprogram/Paper199710.html
inMIND:
https://ash.confex.com/ash/2024/webprogram/Paper212970.html
POLARIX Long-Term F/U:
https://ash.confex.com/ash/2024/webprogram/Paper197938.html

Nov 16, 2024 • 56min
A Bunch of ASHholes Discuss Myeloma Abstracts
In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

Nov 8, 2024 • 48min
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!